Trials / Completed
CompletedNCT04823247
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
A Multicenter, Prospective Observational RWE Study to Assess Patient-reported Wellbeing Using Tildrakizumab in a Live Setting - POSITIVE Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 782 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an ethics-approved, multi-national, multi-site Phase IV, 1-cohort prospective observational study. The main purpose of this study is to assess the effect of tildrakizumab on the overall wellbeing in patients with moderate-to-severe psoriasis using the 5-item World Health Organization Wellbeing Index (WHO-5) questionnaire.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tildrakizumab | As provided in real world clinical practice. |
Timeline
- Start date
- 2021-11-22
- Primary completion
- 2025-01-09
- Completion
- 2025-01-09
- First posted
- 2021-03-30
- Last updated
- 2025-05-11
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04823247. Inclusion in this directory is not an endorsement.